Date: 2017-03-15
Type of information: Nomination
Compound:
Company: Adaptimmune (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 15, 2017, Adaptimmune Therapeutics announced that it has broadened its executive team with the appointment of co-founder, Helen Tayton-Martin to the newly-created role of Chief Business Officer, and Mr. William (Bill) Bertrand, Jr., as Chief Operating Officer. Both appointments are effective immediately.
- Dr. Tayton-Martin has transitioned from her prior role as COO to the new CBO position that will see her focus entirely on optimizing the strategic and commercial opportunity for the Company’s assets. Her new role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, partnerships and commercial planning. She will retain responsibility for alliances including the strategic partnership with GSK.
- Mr. Bertrand, a highly experienced senior leader within the U.S. biotech industry, will assume responsibility for a range of operational functions, including compliance, risk management, human resources and legal/IP, based at Adaptimmune’s U.S. headquarters in Philadelphia. Mr. Bertrand will work closely with Dr. Tayton-Martin and the rest of the executive team in helping to prepare Adaptimmune for its next stage of development.
Financial terms:
Latest news:
Is general: Yes
